Business Context and Reporting Period
This Form 8-K, dated January 22, 2018, is filed by Avista Healthcare Public Acquisition Corp. (AHPAC), a Cayman Islands exempted company and emerging growth company. The report details a material amendment to the proposed business combination between AHPAC and Envigo International Holdings, Inc. (Envigo). The filing specifically addresses changes to the transaction agreement executed on January 21, 2018.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period, as this is a current report regarding a transaction amendment rather than a periodic financial statement. Key transactional financial adjustments include:
- Consideration Reduction: The aggregate consideration payable to the Selling Equityholders has been reduced.
- Warrant Elimination: The payment by AHPAC for 4,100,000 Private Placement Warrants (to purchase one-half of one AHPAC Class A ordinary share) to be provided to Selling Equityholders has been eliminated.
- Share Surrender: Class B Holders (Parent Sponsor and certain directors) agreed to surrender 3,875,000 Class B ordinary shares and 4,100,000 Private Placement Warrants immediately prior to the consummation of the First Merger.
Material Changes Versus Prior Period
The primary material change is the execution of Amendment No. 3 to the Transaction Agreement, which modifies the terms originally set in August 2017 and subsequently amended in November and December 2017. Specifically, the amendment reduces the total payout to selling shareholders and removes the obligation for AHPAC to pay for specific warrants previously allocated to those shareholders. Additionally, an Amended and Restated Parent Sponsor Letter Agreement was executed to facilitate the surrender of Class B shares and warrants by the sponsor group.
Guidance, Outlook, and Risks
Outlook and Process: The business combination remains in progress. AHPAC has filed a preliminary proxy statement and intends to file and mail a definitive proxy statement to shareholders for voting on the proposed combination. The definitive proxy statement will be mailed once a record date is established.
Risks and Contingencies: The filing includes a standard disclaimer stating that the report does not constitute an offer to sell or a solicitation of an offer to buy securities. The transaction is contingent upon shareholder approval and the filing of necessary regulatory documents. Investors are advised to review the preliminary and definitive proxy statements for detailed risk factors and participant information.
Important Facts for Investor Verification
- Verify the specific dollar amount of the reduced aggregate consideration payable to Selling Equityholders in the full text of Amendment No. 3 (Exhibit 2.1).
- Confirm the final terms of the share and warrant surrender by Class B Holders as detailed in the Amended and Restated Letter Agreement (Exhibit 2.2).
- Review the upcoming definitive proxy statement for the final vote date, record date, and any further material changes to the deal structure.
- Note that the filing text does not provide updated financial performance data for Envigo or AHPAC; refer to separate periodic filings for operational metrics.